Armata Pharmaceuticals
ARMP
21 hedge funds and large institutions have $4.59M invested in Armata Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.
0.07% less ownership
Funds ownership: 4.71% → 4.64% (-0.07%)
9% less funds holding
Funds holding: 23 → 21 (-2)
18% less capital invested
Capital invested by funds: $5.62M → $4.59M (-$1.03M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$386K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$273K |
| 3 |
SF
Synovus Financial
Columbus,
Georgia
|
+$97K |
| 4 |
SSB
Sandy Spring Bank
Olney,
Maryland
|
+$2.99K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$644 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$621K |
| 2 |
BlackRock
New York
|
-$162K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$43.9K |
| 4 |
Renaissance Technologies
New York
|
-$30K |
| 5 |
Millennium Management
New York
|
-$22.5K |
ARMP Hedge Fund Activity: Q2 2021 in Review
21 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q2 2021, worth a combined $4.59M — down 18% from $5.62M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ARMP and 1 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $386K. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $621K sold.
- 21 institutional investors held Armata Pharmaceuticals (ARMP) as of Q2 2021, down from 23 in Q1 2021.
- Funds reported $4.59M of Armata Pharmaceuticals stock for Q2 2021, down 18% quarter-over-quarter.
- 1 fund opened new Armata Pharmaceuticals positions in Q2 2021 and 3 closed out, a net change of -2 holders.
- The largest Armata Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $386K added.
- The largest Armata Pharmaceuticals seller in Q2 2021 was Loomis, Sayles & Company, an estimated $621K sold.
Based on aggregated 13F filings for Q2 2021.